Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Osimertinib–savolitinib led to significantly longer progression-free survival than platinum–pemetrexed (hazard ratio for disease progression or death, 0.55; 95% confidence interval [CI], 0.42 to 0.72; P<0.001), as well as significantly longer overall survival (hazard ratio for death, 0.68; 95% CI, 0.50 to 0.91; P=0.01; final analysis).
Appeared: Tuesday, October 27. New England Journal of Medicine. Peer-reviewed journal.